PBYI - プ―マ・バイオテクノロジ― (Puma Biotechnology Inc)

PBYIのニュース

   Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference  2021/01/04 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present a Puma Biotechnology update at H.C. Wainwright's BioConnect VIRTUAL Conference beginning on Jan. 11, 2021 at 6:00 am EST.
   Breast cancer treatment research wins €800,000 SFI award  2020/12/09 11:51:05 SiliconRepublic
The Strategeic Partnerships Award was funded in equal parts by Science Foundation Ireland and Puma Biotechnology.
   Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted  2020/12/02 13:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.
   Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer  2020/11/05 21:07:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.
   Puma Biotechnology Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.
   Breast cancer treatment research wins €800,000 SFI award  2020/12/09 11:51:05 SiliconRepublic
The Strategeic Partnerships Award was funded in equal parts by Science Foundation Ireland and Puma Biotechnology.
   Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted  2020/12/02 13:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.
   Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer  2020/11/05 21:07:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.
   Puma Biotechnology Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.
   Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results  2020/10/22 20:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On November 5, 2020, Puma Biotechnology will issue its 3Q-2020 financial results after market close and host a conference call at 1:30 p.m. PST.
   Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted  2020/12/02 13:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.
   Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer  2020/11/05 21:07:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.
   Puma Biotechnology Reports Third Quarter 2020 Financial Results  2020/11/05 21:05:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.
   Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results  2020/10/22 20:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--On November 5, 2020, Puma Biotechnology will issue its 3Q-2020 financial results after market close and host a conference call at 1:30 p.m. PST.
   Puma Biotechnology Inc (NASDAQ:PBYI) Given Consensus Rating of “Hold” by Analysts  2020/10/20 19:16:53 Transcript Daily
Shares of Puma Biotechnology Inc (NASDAQ:PBYI) have earned an average recommendation of “Hold” from the twelve analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 12 […]

calendar